TBO_ZH

TBO_ZH

Interesting development in Germany. ABC correction from the top with strong Support and interesting entry Points. A nice aggressive call.

TBO_ZH

Elliott Waves again plus mini SHS Good story good chart! check story from my last bull case

TBO_ZH

SL @ 92.00/90 Moving turning UP, Breakout with long white marubozu,

TBO_ZH

graphics getting more and more important -> also within smartphones ? •Nvidia reported strong Q2 earnings, with revenue and earnings growing in the double-digits. •AMD's GPU issues have not affected Nvidia, with its GTX gaming GPUs growing by 10%. •Growth opportunities including a growing PC market, the automotive market and the enterprise market should lead to...

TBO_ZH

HPQ did not look attractive for many years but it seems it's back on track. Fundamentally and technically. For cautious investors await 38+ breakout - but if you have a look at the daily chart we see a "buy the dips" opportunity.

TBO_ZH

it seems MA is ready to push again to the 52w high of around 84.60. Easy BUY with near stopp loss at 74.50.

TBO_ZH

tested major as well as minor support and JCI is forming a rebound pattern with a broader doji and bullish reversal candles. Minor resistance @ 46.64 which has to be taken in order to at least get back to 200 mvg and then 51.00 levels.

TBO_ZH

US Financials look extremely good. XLF US hitting new highs. Bull scenario.

TBO_ZH

in at 82 catching early move, still must have Since December 2013 Sovaldi is available in the US and since January 2014 in some European countries while approvals in various significant markets are still pending. Based on its medical importance, I expect more launches in due time. Medicare (US national social insurance program) projects costs of USD 6.5bn in...

TBO_ZH

Although figures not that good as expected still very good story behind the company and holding breakout position after earnings miss. (CELG believes Otezla has achieved a market share lead for psoriatic arthritis shortly after its launch in April). Good fancy LT Buy and Hold. Downside limited.